Overview
Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)
Status:
Completed
Completed
Trial end date:
2013-05-01
2013-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The primary objective of this study is to evaluate the impact of chronic hepatitis C (CHC), and the treatment thereof with peginterferon alpha-2b (PEG) and ribavirin (RBV) according to standard clinical practice, on the health-related quality of life (HRQL) of a cohort of participants throughout 72 weeks of follow-up. HRQL was assessed using the 36-Item Short-Form Health Survey (SF-36) and the Chronic Liver Disease Questionnaire-Hepatitis C Virus (CLDQ-HCV).Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Merck Sharp & Dohme Corp.Treatments:
Interferon-alpha
Peginterferon alfa-2b
Ribavirin
Criteria
Inclusion Criteria:- Participants diagnosed with chronic hepatitis C (CHC)
- Participants with HCV genotype 1
- Participants who, at the time of the study, are referred to the Hospital Pharmacy
Service to begin treatment with PEG and RBV for 48 weeks
- Available to understand and to give Informed Consent
Exclusion Criteria:
- Participants co-infected with Human Immunodeficiency Virus (HIV) or Hepatitis B Virus
(HBV)